Released May 11, 2023, after the close
10-Q filed May 11, 2023, 41 days after period end · 0001390478-23-000012
Q1 2023 · 10-Q
Revenue$0.00$0.00 −100.0% vs Q1 2022no prior Q4 2022 on file
Net Income-$11.10M-$11.10M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.47-$0.47 N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$11,281,000N/M
Operating Cash Flow-$12,127,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $0.00 | $1.00M | $5.70M | $0.00 |
| Net Income | -$11.10M | -$16.74M | -$2.40M | -$4.14M |
| EPS Diluted | -$0.47 | -$1.05 | -$0.16 | -$0.66 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR